Hexima Limited

Equities

HXL

AU0000111932

Biotechnology & Medical Research

Market Closed - Australian S.E. Other stock markets 02:10:10 2024-04-22 am EDT			5-day change	1st Jan Change
0.013 ^AUD	0.00%		0.00%	-27.78%

Mar. 22	Hexima Secures R&D Tax Rebate for Fiscal Year 2023	MT
Mar. 19	Hexima Changes Address	MT

Hexima Limited Receives Requisition Notice from Merchant Biotech Fund

December 13, 2022 at 06:26 pm EST

On December 14, 2022, Hexima Limited announced that it has received a requisition notice from Merchant Biotech Fund requesting the general meeting of the Company will be held on January 31, 2023, that to remove Michael Aldridge, Jake Nunn and Scott Robertson as a director of the Company and to appoint Chris Mews as a director of the Company.

Latest news about Hexima Limited

Hexima Secures R&D Tax Rebate for Fiscal Year 2023	Mar. 21	MT
Hexima Changes Address	Mar. 19	MT
Hexima Limited Announces Change of Address	Mar. 19	CI
Hexima Limited Reports Earnings Results for the Half Year Ended December 31, 2023	Feb. 28	CI
Hexima Limited Announces the Resignation of Dr. Nicole Van Der Weerden as Director	Nov. 29	CI
Hexima Limited Appoints Phillip Hains as A Non-Executive Director	23-09-18	CI
Hexima Limited Appoints Geoffrey Kempler as Managing Director	23-09-05	CI
Hexima Limited Announces Executive Changes	23-09-05	CI
Hexima Limited Reports Earnings Results for the Full Year Ended June 30, 2023	23-08-31	CI
Hexima Limited Announces Resignation of Mr. Steven Skala as an Alternate Director	23-05-11	CI
Hexima Limited Reports Earnings Results for the Half Year Ended December 31, 2022	23-02-27	CI
Hexima Limited Declares Voting Results	23-01-30	CI
Arovella Therapeutics Appoints COO	23-01-03	MT
Hexima Acting CEO to Step Down	22-12-22	MT
Nicole Van Der Weerden to Step Down as CEO of Hexima Limited	22-12-22	CI
Hexima Receives AU$6 Million Tax Incentive Refund from Australian Taxation Office	22-12-14	MT
Hexima Limited Receives Requisition Notice from Merchant Biotech Fund	22-12-13	CI
Hexima Limited Announces Board Changes	22-12-04	CI
10,150,000 Options of Hexima Limited are subject to a Lock-Up Agreement Ending on 1-DEC-2022.	22-11-30	CI
6,925,878 Ordinary Shares of Hexima Limited are subject to a Lock-Up Agreement Ending on 1-DEC-2022.	22-11-30	CI
Hexima Limited Announces Change of Address	22-09-12	CI
Hexima Limited Reports Earnings Results for the Full Year Ended June 30, 2022	22-08-30	CI
Hexima Managing Director, CEO Steps Down	22-08-02	MT
Hexima Limited Announces Management Changes	22-08-01	CI
Hexima Limited Announces Phase II Results of Pezadeftide	22-07-10	CI

Chart Hexima Limited

Duration

Period

More charts

Company Profile

Hexima Limited is an Australia-based company. The Company is exploring opportunities for transactions with third parties which could enable the potential value of the Companyâs assets, including its intellectual property and other intangible assets, to be realized.

Sector

Biotechnology & Medical Research

Calendar

2024-08-27 - Q4 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Annual profits - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
HEXIMA LIMITED	-27.78%	1.41M
IQVIA HOLDINGS INC.	+1.51%	42.59B
MODERNA, INC.	+8.57%	40.65B
LONZA GROUP AG	+49.22%	40.57B
CELLTRION, INC.	-12.36%	26.77B
ICON PUBLIC LIMITED COMPANY	+8.92%	24.81B
ALNYLAM PHARMACEUTICALS, INC.	-25.13%	18.17B
MEDPACE HOLDINGS, INC.	+29.17%	12.05B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.12%	11.7B
UNITED THERAPEUTICS CORPORATION	+6.35%	11.1B

Other Biotechnology & Medical Research